Involvement of the Fas system in hepatitis C virus recurrence after liver transplantation

Liver Transplantation

Volumn 6, Issue 5, 2000, Pages 562-569

  Crespo, Javier ^a   Rivero, Monteserrat ^a   Mayorga, Marta ^a   Fabrega, Emilio ^a   Casafont, Fernando ^a   Gomez Fleitas, Manuel ^a   Pons Romero, Fernando ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; FAS ANTIGEN;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPEROXIDASE STAINING; LIVER CELL; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; NICK END LABELING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE;

EID: 0033822118     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2000.9742     Document Type: Article

References (36)

1. Hepatitis C infection in patients undergoing liver retransplantation
2. Predictors of patient and graft survival following liver transplantation for hepatitis C
3. Hepatitis C virus recurrence after liver transplantation: Relationship to anti-HCV core IgM, genotype, and level of viremia
4. Biochemical and histologic evaluation of recurrent hepatitis C following orthotopic liver transplantation
5. Recurrent hepatitis C virus infection after liver transplantation: Immunohistochemical assessment of the viral antigen
6. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes
7. Hepatitis C virus genotypes and quantification of serum hepatitis C RNA in liver transplant recipients Relationship with histologic outcome of recurrent hepatitis C
8. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation
9. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury
10. Death receptors in liver biology and pathobiology
11. Apoptosis in liver disease
12. Mechanisms of liver damage
13. Fas and Fas ligand: A death factor and its receptor
14. The Fas death factor
15. Death associated proteins (DAPs): From gene identification to the analysis of their apoptotic and tumor suppressive functions
16. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis
17. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
18. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing
19. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity
20. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection
21. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL
22. In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases
23. Essential roles of the Fas ligand in the development of hepatitis
24. Viral replication in patients with concomitant HBV and HCV infections
25. Formulation and application of a numerical scoring system for assessing histological activity in asymptotic chronic active hepatitis
26. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
27. Lethal effect of the anti-Fas antibody in mice
28. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C
29. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C
30. Fas ligand, tumor necrosis factor-alpha expression, and apoptosis during allograft rejection and tolerance
31. Bile salts induce hepatocyte apoptosis by increasing cell surface trafficking of Fas
32. Human hepatocytes produce an isoform of FAS that inhibits apoptosis
33. Serum levels of soluble Fas antigen in chronic hepatitis C patients
34. Suppression of apoptotic cell death by hepatitis C virus core protein
35. Suppression of actinomycin D-induced apoptosis by the NS3 protein of hepatitis C virus
36. Fas antigen expression of hepatocytes and its modification by immunosuppressants